首页> 外文期刊>Bone marrow transplantation >Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease
【24h】

Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease

机译:结肠和肝脏组织损伤使用甲基化SESN3和PTK2B基因在急性移植物与宿主疾病患者中循环无细胞DNA中的基因

获取原文
获取原文并翻译 | 示例
       

摘要

Cell-free DNA (cfDNA) has been investigated in acute graft-versus-host disease (aGvHD) following allogeneic cell transplantation (HSCT). Identifying the tissue of origin of cfDNA in patients with aGvHD is relevant particularly when a biopsy is not feasible. We investigate the cfDNA tissue of origin in patients with aGvHD using methylated gene biomarkers. Patients with liver, colon, or skin aGvHD (n = 28) were analyzed. Liver- and colon-derived cfDNA was measured using a colon- (SESN3) and liver (PTK2B)-specific methylation marker with digital droplet PCR. A statistically significant difference (p < 0.001) in PTK2B and SESN3 concentration was observed between patients with colon or liver GvHD and the control group. For SESN3 and PTK2B the area under the curve in the receiver-operating characteristic (ROC) space was 0.952 (95% CI, 0.888-1p < 0.001) and 0.971 (95% CI, 0.964-1p < 0.001), respectively. Thresholds to differentiate aGvHD from non-aGvHD in colon were 0 (sensitivity: 0.905; specificity: 0.989) and liver 1.5 (sensitivity: 0.928; specificity: 0.910). Clinical improvement of liver or colon aGvHD resulted in PTK2B and SESN3 reduced concentration. Whereas, in those patients without improvement the PTK2B and SESN3 level remained stable or increased. The PTK2B liver-specific marker and the SESN3 colon-specific marker and their longitudinal analysis might improve aGvHD detection.
机译:在同种异体细胞移植(HSCT)之后,已经研究了无细胞DNA(CFDNA)在急性接枝腹膜疾病(AGVHD)中。鉴定AGVHD患者的CFDNA的起源组织是特别相关的,特别是当活组织检查不可行时。我们使用甲基化基因生物标志物研究AGVHD患者的起源CFDNA组织。分析肝脏,结肠或皮肤AGVHD(n = 28)的患者。使用具有数字液滴PCR的结肠(SESN3)和肝脏(PTK2B)的甲基化标记测量肝脏和结肠衍生的CFDNA。在结肠或肝GVHD和对照组的患者之间观察到PTκ2B和SESN3浓度的统计学上显着差异(P <0.001)。对于SESN3和PTK2B,接收器操作特性(ROC)空间中的曲线下的区域分别为0.952(95%CI,0.888-1P <0.001)和0.971(95%CI,0.964-1P <0.001)。将AGVHD在结肠中的非AGVHD区分为0(灵敏度:0.905;特异性:0.989)和肝1.5(灵敏度:0.928;特异性:0.910)。肝脏或结肠AGVHD的临床改善导致PTK2B和SESN3降低浓度。然而,在那些没有改善的患者中,PTK2B和SESN3水平保持稳定或增加。 PTK2B肝细胞特异性标记和SESN3特异性标记及其纵向分析可能改善AGVHD检测。

著录项

  • 来源
    《Bone marrow transplantation》 |2021年第2期|共7页
  • 作者单位

    Freiburg Univ Med Ctr Dept Hematol Oncol &

    Stem Cell Transplantat Freiburg Germany;

    Freiburg Univ Med Ctr Dept Hematol Oncol &

    Stem Cell Transplantat Freiburg Germany;

    Freiburg Univ Med Ctr Dept Hematol Oncol &

    Stem Cell Transplantat Freiburg Germany;

    Freiburg Univ Med Ctr Dept Hematol Oncol &

    Stem Cell Transplantat Freiburg Germany;

    Freiburg Univ Med Ctr Dept Hematol Oncol &

    Stem Cell Transplantat Freiburg Germany;

    Freiburg Univ Med Ctr Dept Hematol Oncol &

    Stem Cell Transplantat Freiburg Germany;

    Freiburg Univ Med Ctr Dept Hematol Oncol &

    Stem Cell Transplantat Freiburg Germany;

    Freiburg Univ Med Ctr Dept Hematol Oncol &

    Stem Cell Transplantat Freiburg Germany;

    Freiburg Univ Med Ctr Dept Hematol Oncol &

    Stem Cell Transplantat Freiburg Germany;

    Freiburg Univ Med Ctr Dept Hematol Oncol &

    Stem Cell Transplantat Freiburg Germany;

    Freiburg Univ Med Ctr Dept Hematol Oncol &

    Stem Cell Transplantat Freiburg Germany;

    Freiburg Univ Med Ctr Dept Hematol Oncol &

    Stem Cell Transplantat Freiburg Germany;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号